Skip to main content

Qiagen Snips Ribbon on New US Headquarters

NEW YORK, Jan. 11 - Qiagen Sciences has opened its new manufacturing complex in biotech-rich Germantown, Md., the company announced on Friday.

 

The 200,000-square-foot facility, which becomes Qiagen's new North American headquarters for manufacturing, production, and research and development, will employ 100 R&D personnel and more than 200 manufacturing staff to develop and process DNA separation and purification products.

 

Manufacturing activities will start by the end of February, the company said. Qiagen is based in Venlo, the Netherlands.

 

Qiagen generates approximately 60 percent of its consolidated revenues in the United States, said Peer M. Schatz, CFO for Qiagen. The new facility "should have a positive impact on the company's exposure to currency fluctuations, as well as enhance logistics," he added.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.